Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Acne Infection

Acne Infection

Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

Drug Toxicity: Allergic Reactions

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Advanced hybrid nanocomposites for infrastructure renewal: enhanced shear and flexural performance in load-bearing applications.

Scientific reports·2026

Same author

Effect of infill parameters and thermal annealing on the mechanical behavior of FDM 3D-printed polymer.

Scientific reports·2026

Same author

Insights into particle dispersion and damage mechanisms in functionally graded metal matrix composites with random microstructure-based finite element model.

Scientific reports·2024

Same author

Characterization of steel lined with multilayer micro/nano-polymeric composites.

Scientific reports·2022

Same author

Characterization and performance evaluation of Cu-based/TiO<sub>2</sub> nano composites.

Scientific reports·2022

Same author

Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real-world conditions in Germany - The non-interventional study NIELS.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021

Same journal

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022

Same journal

[Viral infections of the skin].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022

Same journal

[Viral exanthems in children].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022

Same journal

[Erratum to: Digital health applications and data protection].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022

Same journal

[Virus-induced exanthems in returning travellers].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022

Same journal

[Venous ulcus cruris-Surgical treatment].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022

See all related articles

Search research articles

Related Experiment Video

Updated: May 12, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

[Erlotinib-induced acneiform eruption].

R U Wahl¹, M Megahed

¹Klinik für Allergologie und Dermatologie, Universitätsklinikum RWTH Aachen, Pauwelsstr. 30, 52074 Aachen, Germany. rwahl@ukaachen.de

Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete

|March 29, 2013

Summary

This summary is machine-generated.

Erlotinib, an EGFR inhibitor, can cause a papulopustular rash in lung cancer patients. This skin condition was effectively managed with topical and systemic antimicrobial and anti-inflammatory treatments.

Related Experiment Videos

Last Updated: May 12, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Area of Science:

Oncology
Dermatology
Pharmacology

Background:

A 73-year-old male patient diagnosed with pulmonary adenocarcinoma for three years.
Patient received Epidermal Growth Factor Receptor (EGFR) inhibitor erlotinib for 18 months.

Observation:

Developed a progressive papulopustular rash on the face, trunk, and thighs during erlotinib treatment.
The rash was characterized as a side effect of the EGFR inhibitor therapy.

Findings:

Topical treatment with methylprednisolone and nadifloxacin provided significant improvement.
Short courses of systemic doxycycline and ciprofloxacin further controlled the skin condition.

Implications:

Highlights the common dermatological side effects of EGFR inhibitors in cancer therapy.
Demonstrates effective management strategies for drug-induced skin reactions.
Informs clinical practice regarding the monitoring and treatment of rash in patients on erlotinib.